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The effects of N-methylformamide on artificial and spontaneous
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Summary The effects of the differentiation-inducing polar solvent N-methylformamide (NMF) on artificially
induced and spontaneous metastases from a murine hepatocarcinoma (HCA-1) in C3Hf/Kam mice were
investigated. Exposure of HCA-1 cells in vitro for 6 days to 1.0% or 1.25% NMF resulted in an increase in
the number of lung nodules formed in mice when these cells were injected into their tail veins. This in vitro
NMF exposure increased cell volume and induced only a slight amount of cytotoxicity. Administration of
NMF to mice I day before i.v. tumour cell inoculation resulted in a dose-dependent increase in the number of
lung nodules formed, beginning at an NMF dose of 600mgkg-1. NMF caused a similar magnitude of
metastasis enhancement in immunosuppressed mice. However, when the maximum dose tested
(1,800 mg kg- ') was administered as 6 daily fractions of 300 mgkg- each, no increase in artificial metastases
was detected. Administration of NMF to mice one day after i.v. tumour cell injection resulted in a dose-
dependent decrease in the number of lung nodules. In mice bearing 5-6mm HCA-1 leg tumours, treatment
with 6 daily fractions of NMF (300mgkg- each) significantly reduced the number of spontaneous
pulmonary metastases, yet had very little effect on the growth of the primary tumour. These data suggest
that, in a clinically relevant treatment setting, NMF can reduce metastasis formation.
Maturational agents are a class of antitumour compounds
characterized by their ability to induce malignant cells to
form better-differentiated phenotypes. In addition, some of
these agents render tumour cells more susceptible to the
cytotoxic effects of ionizing radiation (Leith et al., 1982;
Iwakawa et al., 1986) and certain antineoplastic drugs
(Spremulli & Dexter, 1984; Tofilon et al., 1986). The polar
solvent N-methylformamide (NMF) belongs to this class of
agents and is currently undergoing phase 11 trials in the
treatment of human tumours (Sternberg & Yagoda, 1985).
Exposure of human and rodent leukaemic cells in vitro to
NMF was found to result in terminal differentiation (Collins
et (1l., 1978). However, cells from most solid tumours
exposed to NMF do not terminally differentiate, but rather
proceed to form so-called better-differentiated or less
malignant phenotypes (Spremulli & Dexter, 1984). Changes
in cellular characteristics reported to be associated with the
better-differentiated phenotypes include alterations in cell
morphology, reduction in the rate of cell proliferation and
clonogenicity, and the production of specialized cell
products, characteristics usually associated with differen-
tiated cells. However, upon withdrawal of NMF, tumour
cells revert to their original form.
In addition to the observed cellular changes, it was
hypothesized that the NMF-mediated induction of a better-
differentiated state in malignant tumours should be
accompanied by less aggressive behaviour of these tumours,
including a reduction in metastatic propensity (Spremulli &
Dexter, 1984). While the influence of NMF on the growth of
several experimental solid tumours has been studied (Clarke
et al., 1953; Gescher et al., 1982; Dexter ct al., 1982), little is
known about the effect of maturational agents on either the
formation or therapy of tumour metastases. Cells treated in
v'itro with the maturational agent DMSO (Takenaga, 1984)
or exposed to conditions that lead to maturation (Bennett et
al., 1986) were reported to have increased lung colonization
ability after i.v. injection, suggesting that maturational
agents might promote metastasis formation rather than be
antimetastatic. Since NMF has already entered clinical trials,
it is important to establish whether it influences metastasis
formation. We report here studies designed to investigate the
effects of NMF on three aspects of metastases of a murine
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hepatocarcinoma (HCA-1): lung colonization, established
artificial micrometastatic foci and spontaneous metastasis.
Exposure of HCA-1 cells in vitro results in an increase in
cell doubling time, a reduction in clonogenicity and an
increase in cell volume (Tofilon et al., 1986), changes
associated with a better differentiated phenotype (Spremulli
& Dexter, 1984).
Materials and methods
Mice
Inbred male C3Hf/Kam mice bred and maintained in our
own specific pathogen-free mouse colony were used. Mice
were 9 to 12 weeks old at the beginning of each experiment.
Tumours
In these studies, a spontaneously developed hepatic
carcinoma (HCA-I) syngeneic to C3Hf/Kam mice was used.
The tumour, generously provided by Robert Sedlacek
(Massachusetts General Hospital, Boston, MA), is highly
metastatic and nonimmunogenic (Milas et al., 1986). Single-
cell suspensions were prepared by trypsin digestion of non-
necrotic tumour tissue (Milas et al., 1974). Viability of cells
was greater than 950% as determined by phase contrast
microscopy and trypan blue exclusion.
To generate leg tumours, mice each received an injection
of 5 x I05 viable tumour cells into the right hind thigh.
When tumours grew to 5-6mm in diameter, NMF treatment
was initiated. To obtain tumour growth curves, three
mutually orthogonal diameters of tumours were measured
three times per week with a vernier caliper, and the mean
values were calculated. Mice were killed 22 days after the
initiation of NMF treatment, their lungs were removed, and
the number of lung metastases in each was determined.
To produce tumour micrometastases in the lung, I x 105
viable HCA-1 cells were suspended in 0.50 ml of Hsu's
medium (Grand Island Biological Co., Grand Island, NY)
and injected into the tail vein of each mouse. Fourteen days
after tumour cell injection, mice were killed, and the number
of lung nodules in each was determined using the method
described earlier (Milas et al., 1975).
NMF treatment in vivo
NMF was diluted in Solution A (8.0 g NaCI; 0.4 g KCI;
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1.0 g glucose; 0.35 g NaHCO3 1- water), stored in the dark,
and administered as an i.p. or s.c. injection. In addition,
NMF was also administered through an osmotic minipump
(Alza 2001). Minipumps were implanted s.c. using sodium
pentobarbital (Nembutal) anaesthesia and delivered 1 ilh-'
of a 313 mgml-' solution of NMF, which is equivalent to
300 mgkg -day-1. Pumps were removed under anaesthesia
6 days after implantation.
Cell culture
Hepatocarcinoma cells were grown in monolayer culture in
Hsu's medium containing 20% foetal calf serum and plating
efficiency was determined as described elsewhere (Tofilon et
al., 1985). Cells were exposed to NMF in normal growth
medium for 6 days. Cell volume was determined using a
Coulter Channelyzer and the appropriate standards.
Results
To determine the effects of in vitro NMF exposure on
HCA-1 artificial metastasis formation, cells were grown in
monolayer culture in medium containing 1.0% or 1.25%
NMF for 6 days (at which time they were still in exponential
phase), were trypsinized, and a single cell suspension of 105
cells was injected into the tail vein of each mouse. A
representative experiment is shown in Table I. Compared
with controls, exposure of HCA-1 cells in vitro to 1.0% or
1.25% NMF resulted in a significant increase in the number
of lung nodules when cells were injected i.v. The
concentrations of NMF used in this experiment produced
only a slight amount of cytotoxicity as determined by in vitro
colony formation (plating efficiency), yet in the groups that
received 1% or 1.25% NMF cell volumes, determined from
the single cell suspensions, were significantly greater than
control. In an additional experiment, cells were grown in 1%
NMF for 6 days and then in NMF-free medium for 3 days
before i.v. injection (data not shown). In this case, the cell
volume and the number of lung colonies formed were similar
to untreated values indicating that, as for other NMF-
induced cellular changes (Spremulli & Dexter, 1984; Tofilon
et al., 1986), the increase in cell volume and lung colonizing
ability are also reversible.
In addition to having influences on the tumour cell,
chemotherapeutic agents administered in vivo can affect the
Table I Effect of in vitro NMF exposure of in vivo artificial
metastasis formation
In vitro properties
Number of Cell volume
Treatnment lung nodulesa Plating efficiencyb (Um3)
Experiment 1
None
NMF (1%)
NMF (1.25%)
13.3+ 3.6
209.0+ 83.3c
184.6+ 35.5C
0.76 +0.05
0.69 +0.03
0.66+0.03
949
1548
1475
HCA-1 cells were grown in vitro in normal growth medium or
medium containing NMF (1% or 1.25%) for 6 days. Cells were then
trypsinized; 1 x 105 cells were suspended in 0.5 ml Hsu's medium and
injected into the tail veins of mice. Fourteen days after tumour cell
injection the mice were killed and the number of lung nodules was
determined. The in vitro plating efficiency and cell volume were also
determined for each treatment group, using the same cell
suspensions. Therefore, in the case of cell volume, only one
suspension was used. It should be noted that the effect of NMF on
cell volume is consistently reproducible (Tofilon et al., 1986).
aValues represent the mean + s.e. The control group and the
group that received 1.25% NMF contained 7 mice each, whereas the
group that received 1% NMF contained 3 mice. bValues represent
the mean of + s.e. for 4 petri dishes. cSignificantly different from
untreated as determined by Student's t test (P<0.001).
Table II Effects of pretreatment on artificial
metastases
NMF pretreatment (mgkg)-'
Untreated
150
300
600
1200
6 x 300
Number of
lung nodules
21.3+ 2.1
18.2+ 2.9
21.9+ 2.9
33.5 + 2.5a
84.9 + 16.0O
21.7+ 4.7
An HCA-1 leg tumour was excised, a single cell
suspension was generated, and I x 105 cells were
injected into the tail veins of the mice. Fourteen
days later the mice were killed and the number of
lung nodules was determined. NMF was
administered as a single i.p. injection 1 day before,
or with the last dose of the 6-daily-dose protocol
given 1 day before, tumour cell injection. Values
represent the mean +s.e. for 6 to 7 mice.
aSignificantly different from untreated as
determined by Student's t test (P<0.01).
host, resulting in an increase in metastasis formation (Milas
& Peters, 1984). Thus, to determine whether NMF,
independent of its effects on the tumour cells, enhances
metastasis formation through an effect on the host, NMF
was administered before tumour cell inoculation. In this
experiment, NMF was delivered in single, graded, i.p. doses
1 day before tumour cell inoculation or as 6 daily bolus
treatments with the last treatment administered 1 day before
tumour cell inoculation. Brindley et al. (1982) found that
24 h after CBA mice were injected i.p. with NMF the plasma
level declined to an undetectable concentration, according to
a gas chromatographic technique. As shown in Table II,
single injections of NMF resulted in a dose-dependent
increase in the number of artificial metastases formed,
whereas a total dose of 1,800mgkg-1 delivered as 6 daily
injections of 300mgkg-1 each did not affect the number of
lung nodules as compared to controls.
The time of NMF pretreatment that results in the greatest
enhancement of metastases was investigated by administering
a single, relatively large dose of NMF (1,200mgkg-1) at
various times before i.v. injection of tumour cells. Fourteen
days after receiving tumour cell injection, mice were killed
and the number of lung nodules was determined. The
maximum enhancement of artificial metastases was obtained
when NMF was given 1 day before tumour cell injection
(Figure 1). Essentially no enhancement was detected when
NMF was administered 10 days before tumour cell injection,
suggesting that whatever host damage is induced by NMF is
repaired within 10 days. However, in contrast to the effect
exerted by the pretreatment with NMF, the administration
of NMF I day after tumour cell injection resulted in a
significant reduction in the number of artificial metastases.
Because suppression of the immune system is a mechanism
by which cytotoxic agents cause enhancement of artificial
metastases, a possibility exists that a similar mechanism is
also involved in NMF-induced metastasis enhancement. If
such a mechanism is involved, then NMF would be less
effective in immunosuppressed animals. To test this
hypothesis, mice were immunosuppressed by exposing them
to 6 Gy of whole body irradiation (WBI) 4 days before
injection of tumour cells. NMF (900mgkg-1) was given on
days 4 and 3 (a total dose of 1,800mgkg-1) before tumour
cell injection. The results, presented in Table III, show that
NMF increased the number of lung nodules by 2-fold in
both unirradiated mice and those given WBI. WBI alone
increased the number of lung nodules. Thus, these data
suggest that the NMF-induced enhancement of artificial
metastases is unlikely to be mediated via suppression of the
immune system.THE EFFECTS OF NMF ON METASTASES
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Figure 1 HCA-I cells (105) obtained from an in vivo tumour cell
suspension, were injected into the tail veins of mice; 14 days later
the mice were killed and the number of lung nodules was
determined. NMF (1,200mgkg-1) was administered in a single
i.p. injection at various times before tumour cell injection (day 0)
and 1 day after tumour cell injection (closed symbols). The open
symbol represents results from untreated mice. Values are the
mean + s.e. for 6 to 8 mice.
Table III Effect of NMF pretreatment on artificial
metastasis formation in whole body irradiation (WBI)
mice
Number oflung
Pretreatment 105 cells 104 cells
6
4
2
U
6x3001
2x6oo0 ax6001
A a . . .
o 300 600 900 1200 1500 1800
NMF (mg kg-1)
Figure 2 HCA-1 cells (105), obtained from in vivo tumour cell
suspension, were injected into the tail vein of mice; 14 days later
the mice were killed and the number of lung nodules determined.
NMF was administered in graded doses (i.p.) 1 day after tumour
cell injection (closed symbols); daily injections (2 x 900mgkg-1,
3x600mgkg- 1 or 6x300mgkg-1) were begun 1 day after
tumour cell injection (open symbols). Values represent the mean
+s.e. for 6 to 7 mice.
Untreated
NMF (900 mgkg- 1)
WBI (6 Gy)
WBI+NMF
81.9+ 3.7
130.9+22.3
155.3 +21.7
314.3 + 51.1
7.7+1.0
13.5 + 1.8
17.6+ 3.1
35.5 +6.4
HCA-1 cells (104 or 105), obtained from an in vivo
tumour cell suspension, were injected into the tail veins
of mice; 14 days later the mice were killed and the
number of lung nodules was determined. WBI (6 Gy)
was administered 4 days before tumour cell injection,
and NMF (900mgkg-1) was given on days 4 and 3
before tumour cell injection. Values represent the mean
+s.e. for 7 to 8 mice.
The data shown in the Figure indicate that, whereas
NMF pretreatment increased metastases formation,
administration of NMF 1 day after tumour cell injection
resulted in a decrease in the number of lung nodules. To
further investigate the effects of NMF on existing artificial
metastases, day after tumour cell injection, NMF was
administered as a single i.p. injection or daily treatment was
initiated. Mice were killed 14 days after tumour cell
injection, at which time the lung nodules in all groups were
approximately the same size. Administration of single
injections of NMF resulted in a dose-dependent decrease in
the number of lung nodules (Figure 2). Administration of a
total NMF dose of 1,800mgkg- 1 divided into 2, 3, or 6
daily fractions also reduced the number of lung nodules;
however, the reduction was not as great as with that same
total dose delivered in a single injection.
Data from artificial metastases experiments indicate that
NMF delivered in 6 daily doses of 300 mgkg-1 each before
tumour cell injection does not result in the enhancement of
metastases, but if given after injection, reduces the number
Table IV Effects of NMF on spontaneous metastases
Number of Tumour
NMF treatment (mgkg-1) lung nodules diameter (mm)a
Untreated
6 x 300, i.p.
6 x 300, s.c.
6 x 300, pump
12.8+2.4
4.3+0.8b
6.5+1.2b
6.3 + 1.2b
19.6+0.7
18.4+0.6
19.3 + 1.2
18.5+1.8
HCA-1 leg tumours were generated by injecting 5 x 105 cells
(obtained from an in vivo tumour cell suspension) into the hind right
leg of each mouse. When tumours were 5-6mm in diameter NMF
treatment was initiated and continued for 6 daily i.p. or s.c.
injections of 300mgkg - each or through continual release from an
osmotic minipump implanted s.c. that delivered 300mgkg-1 day- I
for 6 days. Values represent the mean +s.e. for 8 to 9 mice. Mice
were killed 22 days after the initiation of NMF treatment, and the
number of lung nodules was determined.
aMean tumour diameter at the time mice were killed. bSignificantly
different from control as determined by Student's t test (P<0.01).
of lung nodules. Thus, this treatment schedule was used to
determine the effects of NMF on spontaneous pulmonary
metastases from HCA-l tumours in the leg. In this
experiment, to investigate the effects of the route of
administration, NMF treatment was initiated when tumours
were 5-6 mm in diameter and, consisted of 6 daily i.p. or s.c.
injections of 300 mgkg-1 or 300mgkg-1 day-1 delivered for
6 days by an s.c. implanted minipump. Mice were killed 22
days after the initiation of NMF treatment, and the number
of lung nodules was determined. For each route of NMF
delivery, 300 mgkg-1 x 6 days resulted in a significant
reduction in the number of spontaneous metastases
compared with that for untreated mice (Table IV). However,
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there was no differences in the sizes of the metastases
between control and treatment groups (data not shown).
NMF treatment slowed tumour growth only slightly, with all
tumours being approximately the same size at the time the
mice were killed. These data suggest that NMF has anti-
metastatic actions, yet has very little detectable effect on the
growth of the primary tumour.
In an additional experiment, mice bearing HCA-1 leg
tumours 5-6 mm in diameter were given 6 daily i.p.
injections of NMF (300mgkg-I each); on the seventh day
mice were killed, a tumour cell suspension was prepared, and
the average cell volume in the suspension was determined
according to a Coulter Channelyzer. The tumour cell
suspension generated from untreated mice had an average
cell volume of 480 jim3, whereas that generated from mice
that had received NMF treatment had an average cell
volume of 1,700 jm3. It appears that, as in the in vitro
experiments in Table 1, NMF treatment in vivo also results in
an increase in tumour cell volume.
Discussion
Depending on the experimental setting, NMF exerted both
enhancing and inhibiting effects on tumour metastasis. The
enhancement was observed when mice were treated with
NMF before i.v. inoculation of tumour cells, whereas
reduction resulted when the drug was given after tumour cell
inoculation. This pattern of metastatic effects is very similar
to that reported for a number of cytotoxic agents (Milas &
Peters, 1984). These authors discussed in detail a number of
host mediated possibilities responsible for the enhancement
of metastasis formation caused by cytotoxic agents, which
included immunosuppression, stress-like reaction, and local
capillary damage. Immunosuppression as a possible
mechanism for NMF induced metastasis enhancement can be
excluded on the basis that the HCA-1 tumour is not
immunogenic (Milas et al., 1986), and that it caused a
similar magnitude of metastasis enhancement in both normal
and WBI-immunosuppressed mice (Table III). Although the
tumour is not immunogenic, its cells generated more colonies
in WBI than in normal mice, which can be attributed largely
to pulmonary vasculature damage (Milas & Peters, 1984).
Although local tissue damage and host mediated
mechanisms, other than immunosuppression, may be
responsible for the NMF-induced enhancement of
metastases, it is also quite possible that, analogous to many
other iatrogenic agents that enhance metastasis formation,
NMF acted through the damage of endothelial cells of the
lung vasculature (Milas et al., 1984; Nicolson & Custead,
1985) and (or) through exerting a stress-like reaction upon
the host (Van den Brenk et al., 1974).
A direct effect on tumour cells is also a potential
mechanism by which NMF increased metastasis formation.
Exposure of HCA-1 cells in vitro to noncytotoxic
concentrations of NMF followed by injection of the cells
into the tail veins of mice resulted in an increase in the
number of lung nodules formed compared with that when
untreated cells were used. In the study by Takenaga using
Lewis lung cells (Takenaga, 1984), the increase in artificial
metastases was attributed to a DMSO-mediated increase in
cell adhesiveness and degradative enzyme activity. We did
not measure enzyme activity or cell adhesiveness in HCA-1
cells; however, cell volume was determined and found to be
greater for cells exposed to NMF. The exposure of a colon
adenocarcinoma cell line to NMF was also found to result in
an increase in cell volume (Arundel et al., 1986). Since
tumour cell volume is a factor influencing tumour cell arrest
in the pulmonary vasculature, with larger cells having a
higher probability for arrest and subsequent metastasis
formation (Grdina et al., 1977), it is reasonable to assume
that NMF may have increased the formation of artificial
metastases in the present study partly due to the increase in
cell volume. It is not known why NMF increases cell
volume. The possibility that it acts through accumulation of
cells in a specific phase of the cell cycle can be excluded
since NMF does not perturb cell cycle distribution of either
HCA-1 cells (unpublished observation) or other tumour cells
(Dexter et al., 1987). Whatever mechanism is involved, the
effect of NMF on the ability of cells to exhibit enhanced
lung colonization was transient and was lost by day 3 after
the removal of NMF.
As already mentioned, the dose of NMF is an important
variable in the induction of metastases enhancement: doses
smaller than 600mgkg-' are not effective even if given in
multiple injections. However, whereas NMF administered in
6 daily doses of 300 mgkg- I each before tumour cell
injection did not enhance metastases formation, this NMF
treatment protocol administered 1 day after tumour cell
injection did result in a significant reduction in the number
of lung nodules. In the absence of the production of specific
cell products indicating differentiation, it is not possible
based on this experiment to determine whether the reduction
in artificial metastases was the result of the induction of a
better-differentiated phenotype or of direct cytotoxicity.
However, when NMF (6 x 300 mg kg ) was administered to
mice bearing HCA-I leg tumours of 5-6 mm in diameter,
only a slight growth delay was detected. The difference in NMF
effects on artificial metastases and solid tumours may be the
result of a difference in tumour cell load. Gescher et al.
(1982) found significant antitumour activity against certain
murine tumours when NMF treatment was initiated 1 day
after i.m. tumour cell injection, before tumours were
palpable. Thus, similar to our findings in the artificial
metastases experiment, these authors found NMF to be
effective against a relatively small tumour cell load.
As for the in vitro exposure to NMF, the average cell
volume in a tumour cell suspension obtained from NMF-
treated mice was also increased compared with that from
controls. As was discussed for artificial metastases, the
increase in tumour cell size might be expected to result in an
increase in spontaneous metastases. However, cell volume
was determined in a tumour suspension; whether the volume
of the tumour cells in the actual in situ tumour is increased
remains to be determined. With respect to the influence of
cell size on metastasis formation, it was expected that the
size of the tumour cells shed into the circulation would be of
major importance rather than the size of cell remaining in
the primary tumour.
NMF treatment of mice bearing HCA-1 leg tumours had
only a slight effect on the growth of the primary tumour, yet
significantly reduced the number of spontaneous metastases.
Although it is not possible to conclusively eliminate a
cytotoxic action on the initial lung metastases formed during
the 6-day NMF treatment period, it is tempting to speculate
that the reduction in spontaneous metastases was due to a
direct effect on the primary tumour. It is possible that NMF
treatment results in a decrease in the release of tumour cells
into the circulation. While NMF caused only a slight
reduction in the size of leg tumours, it increased cell volume
by -1.6 times. Thus, NMF-treated tumours are likely to
contain significantly fewer cells than untreated tumours of
the same size; consequently, the probability of the release of
cells into the circulation is less in the treated tumours. In
addition, if NMF increases the adhesiveness of tumour cells,
as DMSO does (Takenaga, 1984), then the likelihood for
their release from the primary tumour is also minimized. As
previously postulated (Spremulli & Dexter, 1984), NMF may
induce tumour cells to form a better-differentiated phenotype
and, thus, to be less aggressive, resulting in a decrease in
metastatic potential. In vitro, the induction of a better-
differentiated phenotype by NMF is accompanied by an
increase in cell volume (Arundel et al., 1985; Tofilon et al.,
1986): the detected increase in cell volume in vivo may reflect
a similar change in phenotype. Obviously, furtherTHE EFFECTS OF NMF ON METASTASES 243
experiments are required to delineate the specific effects of
NMF on the processes involved in both spontaneous and
artificial metastatic spread.
Thus, in the HCA-1 model system enhancement of
artificial metastases can be a side effect of NMF treatment,
but with NMF doses much larger than those used in the
clinic (Ettinger et al., 1985). In addition, the enhancement
was observed only when NMF was given prior to tumour
cell injection. A recent phase I trial found that the dose-
limiting toxic effects of NMF include nausea and vomiting,
anorexia, and liver function abnormalities, with no detection
myelosuppression (Ettinger et al., 1985). The absence of
NMF haematopoietic toxicity combined with the cytotoxic,
chemosensitizing and radiosensitizing effects detected in
experimental tumour models suggest that NMF may be a
useful therapeutic agent when combined with other
treatment modalities. Our present observation that in a
therapeutically relevant experimental setting, NMF in fact
reduces metastasis formation is additional evidence
suggesting the potential usefulness of this agent in cancer
therapy. Currently, we are undertaking experiments to
determine whether the action of NMF on metastases is
dependent on tumour type. The studies presented here
demonstrate that, in order to gain more complete
information on the effect of cancer therapeutic agents on
metastases, it is necessary to investigate the action of such
agents on the different steps in tumour dissemination.
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